PTGS2 and breast cancer: Our initial CRISPR-i screen scored HECTD4 as a suppressor of metastasis initiation by breast cancer patient-derived CTCs, and our follow-up analyses point to a critical effect in anchorage-independent cell proliferation, with COX-2 as a major degradation target.